---
title: "Moderna nearly triples in record S&P 500 move, but analyst sees more volatility ahead"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296457881.md"
description: "Moderna shares surged 176.97% to $174.38, marking the largest one-day gain for an S&P 500 stock this century, driven by positive late-stage results for its personalized mRNA cancer vaccine with Merck. The rally added $44B to its market cap, bringing it to $69.6B and making it the second-best performer in the index for the year. Despite the historic move, analyst Edmund Ingham maintained a Hold rating, citing the need for further clinical validation before full Phase 3 data release. Shares pulled back 14% in premarket trading Thursday as investors took profits."
datetime: "2026-08-20T08:31:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296457881.md)
  - [en](https://longbridge.com/en/news/296457881.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296457881.md)
generator: "portal-rs"
---

# Moderna nearly triples in record S&P 500 move, but analyst sees more volatility ahead


### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)

## Related News & Research

- [Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock](https://longbridge.com/en/news/297959605.md)
- [Moderna Raises $3.0 Billion via 2032 Zero-Coupon Converts; Adds Capped Calls to Limit Dilution](https://longbridge.com/en/news/297697426.md)
- [Moderna Chief Legal Officer Shannon Thyme Klinger disposes of USD 485,271.45 in common shares](https://longbridge.com/en/news/297958452.md)
- [Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs](https://longbridge.com/en/news/297679815.md)
- [Merck (MRK), Why Is Its Latest Update Raising Bigger Questions?](https://longbridge.com/en/news/298090109.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**